Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Validation, 2007
    Validation of Sirtuin 2 Deacetylase as a Therapeutic Target in Parkinson’s disease

    Objective/Rationale:
    A major known risk factor in Parkinson’s disease is the misfolding, aggregation and abnormal accumulation of the protein alpha-synuclein. The goal of the proposed work is to...

  • Rapid Response Innovation Awards, 2007
    Understanding the Role of Glucocerebrosidase in Parkinson's Disease Pathogenesis: Toward a New Genetic Model of Sporadic PD

    Gaucher’s disease is a glycosphingolipid-storage disease in which homozygous mutations are found in the lysosomal enzyme glucocerebrosidase (GBA) gene. PD and Gaucher’s disease share many clinical and...

  • Rapid Response Innovation Awards, 2007
    Target Identification of the Mitochondrial Parkinson's Disease PTEN-Induced Kinase 1

    Mutations in PINK1 can cause Parkinson’s disease in certain familial PD cases. The exact cellular function of PINK1 and the impact of disease-relevant mutations remain unknown. PINK1 is known to...

  • Rapid Response Innovation Awards, 2007
    Development of SHG to Discover Drugs to Selectively Block AlphaS toxicity

    Abnormal aggregation of normal or genetically mutated alpha-synuclein protein has been proposed as one possible mechanism for PD. Drugs that can target this abnormal change in the structure of the...

  • Target Validation, 2007
    Validation of Targets of Small Molecules that Ameliorate Alpha-synuclein Neurotoxicity

    Objective/Rationale:
    Using high-throughput screening, we have identified a small-molecule compound that rescues toxicity in a yeast model of Parkinson’s Disease and in mammalian neurons. This compound...

  • Target Validation, 2007
    PGC-1 Alpha as a Neuroprotective Target in Parkinson’s Disease

    Objective/Rationale:
    Many treatments exist that can help to treat the symptoms of Parkinson's disease. But despite these "Symptoms & Side Effects" treatments, the disease continues to progress, with...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.